Novokinin

Product Name: Novokinin

CAS No: 358738-77-9

Purity: 95%

Molar Mass: 796.0

Chemical Formula: C39H61N11O7

Storage: Store at -20 degree Celsius

Sequence: RPLKPW

Target: angiotensin AT2

Application: Novokinin is an angiotensin AT2 receptor agonist peptide derived from ovokinin, known for its antihypertensive and anti-inflammatory properties. By binding to AT2 receptors, Novokinin promotes vasodilation and reduces blood pressure, making it effective in cardiovascular research. It is used to study hypertension, heart disease, and related metabolic disorders. Additionally, Novokinin has potential applications in developing therapeutic agents for inflammatory diseases and conditions requiring improved blood flow regulation. Its role in modulating the renin-angiotensin system makes it a valuable tool in both pharmacological and clinical research.

Current Research:

Novokinin is a synthetic peptide derived from ovokinin, a fragment of ovalbumin, with a sequence designed to enhance its biological activity. This heptapeptide, [Arg-Pro-Leu-Lys-Pro-Trp], functions as an agonist of the angiotensin AT2 receptor, exhibiting potent antihypertensive, anti-inflammatory, and anorexigenic effects in various models.
In cardiovascular research, Novokinin has been shown to significantly reduce blood pressure in hypertensive animal models. Its interaction with the AT2 receptor promotes vasodilation and enhances endothelial function, suggesting potential therapeutic applications for managing hypertension and related cardiovascular disorders. Its effectiveness, even when administered orally, highlights its promise as a pharmacologically viable candidate.
Beyond its antihypertensive properties, Novokinin has demonstrated notable anti-inflammatory effects. By modulating inflammatory signaling pathways, it reduces the production of pro-inflammatory cytokines, such as TNF-?? and IL-6. This action positions Novokinin as a potential therapeutic agent for inflammatory diseases, including arthritis and autoimmune conditions.
In the realm of metabolic research, Novokinin has exhibited anorexigenic activity by influencing hypothalamic centers involved in appetite regulation. Studies in rodent models have shown that its administration leads to reduced food intake and body weight, making it an intriguing candidate for addressing obesity and metabolic disorders.
Additionally, Novokinin has been investigated for its neuroprotective effects. Through its interaction with the AT2 receptor, it may confer benefits in neurodegenerative diseases by reducing oxidative stress and modulating neuronal signaling pathways.
In summary, Novokinin represents a multifunctional peptide with broad therapeutic potential. Its antihypertensive, anti-inflammatory, and metabolic regulatory effects make it a valuable tool in drug discovery and a promising candidate for treating a variety of cardiovascular, metabolic, and inflammatory conditions. Ongoing research aims to further elucidate its mechanisms of action and optimize its clinical applications.

Reference: Yoshikawa, M., Ohinata, K., & Yamada, Y. (2013). The Pharmacological Effects of Novokinin; a Designed Peptide Agonist of the Angiotensin AT? 2 Receptor. Current pharmaceutical design, 19(17), 3009-3012.